Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 49Thoracic 3Gynecologic 3Tumor-Agnostic 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × IFL protocol × Dermatologic × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡